<DOC>
	<DOCNO>NCT02491606</DOCNO>
	<brief_summary>This study phase 2b , placebo control , randomize , blind study efficacy WR 238605 , new primaquine analog , compare placebo chemosuppression P. falciparum malaria Nyanza Province , western Kenya .</brief_summary>
	<brief_title>Evaluation Weekly Tafenoquine</brief_title>
	<detailed_description />
	<mesh_term>Tafenoquine</mesh_term>
	<criteria>1 . Healthy subject ( male female ) 2 . Age 1855 year 3 . Residing one study villages Nyanza Province entire study 1 . Any cardiovascular , liver , neurologic , renal functional abnormality opinion clinical investigator would place subject increase risk adverse event confuse result . 2 . Female subject pregnant ( Positive serum / plasma HCG test within 48 hour first drug administration ) . 3 . Use antimalarial drug prescribe study physician within 2 week study drug initiation . 4 . Clinically significant abnormality ( include limit abnormal hepatic renal function ) determine history , physical routine blood chemistry complete blood count . 5 . Known hypersensitivity study drug . 6 . Unwilling remain area report drug administration blood draw duration study . 7 . Glucose 6 Phosphate Dehydrogenase ( G6PD ) deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>